Vitamin D slows progression and reduces symptoms of MS.

vitamin dPrevious studies have confirmed the link between the onset of (MS) and low levels of . Now a new study has confirmed that increasing the of slows disease progression and severity of MS symptoms and has an overall protective effect preventing the onset of MS.The estimates that 2.5 million people are affected by . MS is a disease characterised by problems with muscle control and strength, vision, balance, feeling, and thinking. The new study is one of the first to examine levels from the onset of symptoms of their disease.

“Because low levels are common and can be easily and safely increased by oral supplementation, these findings may contribute to better outcomes for many MS patients,” said lead author , professor of epidemiology and at of Public (HSPH).

“The benefits of appeared to be additive to those of interferon beta-1b, a drug that is very effective in reducing MS activity. The findings of our study indicate that identifying and correcting insufficiency should become part of the standard of care for newly diagnosed MS patients,” said Ascherio.

The study consisted of analyzing data obtained from 465 MS patients from 18 European countries, Israel, and Canada who enrolled in 2002 and 2003 in the BENEFIT (Betaseron in Newly Emerging for Initial Treatment) trial, which was aimed at comparing the effectiveness of early versus late interferon beta-1b in treating the disease. The researchers examined levels of correlated with disease symptoms and progression over a period of five years.

It was found that early stage MS patients with adequate levels of had a 57% lower rate of new brain lesions, a 57% lower relapse rate, and a 25% lower yearly increase in lesion volume than those with lower levels of . The study also confirmed that loss in brain volume, was lower among patients with adequate levels.

Source
, Kassandra L. Munger, Rick White, Karl Köchert, Kelly Claire Simon, Chris H. Polman, Mark S. Freedman, Hans-Peter Hartung, David H. Miller, Xavier Montalbán, Gilles Edan, Frederik Barkhof, Dirk Pleimes, Ernst-Wilhelm Radü, Rupert Sandbrink, Ludwig Kappos, Christoph Pohl. as an Early Predictor of Activity and Progression. JAMA Neurology, 2014; DOI: 10.1001/jamaneurol.2013.5993

Be Sociable, Share!

    Leave a Reply

    Your email address will not be published. Required fields are marked *